PMLiVE5d
AstraZeneca gains rights to CSPC’s lipid-lowering therapy in deal worth over $1.9bn
AstraZeneca (AZ) has entered into an exclusive licence agreement worth over $1.9bn to advance CSPC Pharmaceutical Group’s pre ...
PMLiVE5d
ABPI highlights importance of NHS-industry partnerships in improving patient outcomes
Hospitals engaging in industry partnerships were found to be up to 2.5 times more likely to follow NICE guidelines ...
PMLiVE10d
Roche’s Genentech acquires Regor Pharmaceuticals’ CDK inhibitors for $850m upfront
One of the candidates included in the deal has already shown promise in a phase 1a advanced breast cancer study ...
PMLiVE8d
Bristol Myers Squibb’s Opdivo regimen granted FDA approval in NSCLC
Bristol Myers Squibb’s Opdivo (nivolumab) has been approved by the US Food and Drug Administration (FDA) as part of a ...
PMLiVE8d
Top-10 ways for Pharma to leverage AI according to…AI
Like most people these days, I have been experimenting with various artificial intelligence (AI) tools this past year. It’s ...
PMLiVE11d
FDA approves IntraBio’s Aqneursa to treat Niemann-Pick disease type C patients
The US Food and Drug Administration (FDA) has approved IntraBio’s Aqneursa (levacetylleucine) to treat neurological symptoms ...
PMLiVE9d
Unlocking innovation: The power of diversity at Mednet
Diversity and inclusion are critical to business success, particularly when fostering innovation and creativity. At Mednet, ...
PMLiVE11d
Johnson & Johnson’s Yuvanci granted EC approval to treat pulmonary arterial hypertension
Johnson & Johnson’s (J&J) Yuvanci (single tablet combination therapy [STCT] of macitentan and tadalafi) has been approved by the European Commission (EC) as a long-term treatment for pulmonary ...
PMLiVE10d
Sanofi/Regeneron’s Dupixent approved by FDA to treat uncontrolled COPD
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD). The ...
PMLiVE11d
Roche’s injectable C5 inhibitor PiaSky recommended by NICE for rare blood disorder PNH
Roche’s injectable component C5 inhibitor has been recommended by the National Institute for Health and Care Excellence (NICE) to treat the rare blood disorder paroxysmal nocturnal haemoglobinuria ...
PMLiVE15d
AstraZeneca’s Tagrisso approved by FDA to treat EGFR-mutated lung cancer
AstraZeneca’s (AZ) Tagrisso (osimertinib) has been approved by the US Food and Drug Administration (FDA) to treat a new subset of lung cancer patients. The epidermal growth factor receptor ...
PMLiVE15d
UCB shares positive two-year results for Bimzelx in hidradenitis suppurativa
UCB has shared positive two-year results for its inflammatory disease drug Bimzelx (bimekizumab) in moderate-to-severe hidradenitis suppurativa (HS). New data from the phase 3 BE HEARD I and BE HEARD ...